News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Flushing Drug May Tackle Baldness



3/22/2012 7:00:55 AM

Male-pattern baldness may be caused by a protein in the scalp, according to research that raises the possibility drugs being tested by Merck & Co. (MRK) and Actelion Ltd. (ATLN) for other uses might prevent hair loss. Bald spots had an excessive amount of a protein called prostaglandin D2 or PGD2, according to a study in Science Translational Medicine. Merck’s experimental treatment for facial flushing and Actelion’s allergy compound, both in late- stage studies, block the protein.

Read at Bloomberg
Read at HealthDay
Read at BBC News
Read at ScienceDaily
Read at EurekAlert!
Read at MedicalXpress


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES